What the studies show
The trial reported the peptide was well tolerated by the skin over twelve weeks. Decades of cosmetic use at parts-per-million concentrations have produced no safety signal.
A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.
- 1Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin.Int J Cosmet Sci, 2005;27:155–16093 women aged 35–55; 12-week double-blind split-face study of 3 ppm pal-KTTKS versus vehicle. Procter & Gamble authors.
In context
Matrixyl is palmitoyl pentapeptide-4 (pal-KTTKS), a five-amino-acid fragment of type I collagen with a palmitic acid tail added so it can cross the skin barrier. Its human evidence is a 93-woman, 12-week, split-face randomised trial run by Procter & Gamble, which found significant reduction in wrinkles and fine lines against the vehicle control by both instrumental and expert-grader analysis. It is a legal cosmetic ingredient everywhere LYO covers and is not a medicine.
Matrixyl is cosmetic ingredient. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Matrixyl proven to cause safety?
What studies are behind the grade?
Is Matrixyl approved for this?
Other outcomes for Matrixyl
- CWrinkles and fine lines (topical)1 split-face RCT (n=93, 12 wk)
- DCollagen synthesisNone in vivo
Written and maintained by LYO Research — how pages are written and checked. Reviewed 29 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →